MedTrace Logo

Switching From Preserved to Preserved-free Treatments for Glaucoma.

NCT01433900 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2014-05-16

No results posted yet for this study

Summary

A 1-year prospective, randomized, investigator-masked trial comparing the confocal and clinical effects of treatment with unpreserved prostaglandins (tafluprost) versus preserved prostaglandins (latanoprost) in newly-diagnosed glaucoma patients.

Conditions

Interventions

DRUG

Tafluprost

1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)

DRUG

Latanoprost

1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)

Sponsors & Collaborators

  • Paolo Fogagnolo

    lead OTHER

Principal Investigators

  • Luca Rossetti, MD · San Paolo Hospital, Milan, Italy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2013-05-31
Completion
2014-06-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01433900 on ClinicalTrials.gov